Q1 '12 Results (Clavis Pharma) - Apr 27, 2012 - CO-101 / Clavis; Anticipated top-line data from P2 LEAP study in 1st line metastatic pancreatic cancer in Q4 2012; Anticipated European co-promotion decision in 2013; Anticipated NDA filing in 2013; Anticipated MAA filing in 2013
Anticipated MAA filing • Anticipated NDA filing • Anticipated P2 data • Anticipated partnership deal • Pancreatic Cancer
|
|
CO-101
-------
LEAP: 1st line metastatic pancreatic cancer
CP-4126 (CO-101) CLINICAL DEVELOPMENT PLAN
Top line data expected 4Q 2012
-------
Co-promotion decision Europe in 2013
NDA and MAA filings in 2013
-------
|